Brief progress report from the intersocietal working group on differentiated thyroid cancer

Verburg, Frederik A.; Ahuja, Sukhjeet; Avram, Anca M.; Bardiès, Manuel; Bernet, Victor; Bourguet, P.; Führer-Sakel, Dagmar; Draganescu, C.; Daniels, Gilbert H.; Greenspan, Bennett S.; Güleç, Seza A.; Jonklaas, Jacqueline; Luster, Markus; Oyen, W.J.G.; Smit, Johannes; Tuttle, R. Michael; Zerdoud, Slimane; Nostrand, Douglas Van

doi:10.1007/s00259-020-04744-8

Cited by 6 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reasons for the equipoise are manifold, and only to be unfolded as the oncobiology of thyroid cancer is better understood. The American Thyroid Association (ATA), the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging have established an intersocietal working group to address the current controversies and evolving concepts in thyroid cancer, and to publish expert opinion articles reflecting the intersocietal collaboration and consensus (1)(2)(3). The article is organized to provide a clinical and technical background related to the topic of interest followed by a discussion of current approaches, future directions, and the working group consensus statements.…”

Section: Introductionmentioning

confidence: 99%

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Güleç

Ahuja

Avram

et al. 2021

Thyroid

Self Cite

View full text Add to dashboard Cite

Background: The American Thyroid Association (ATA), the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging have established an intersocietal working group to address the current controversies and evolving concepts in thyroid cancer management and therapy. The working group annually identifies topics that may significantly impact clinical practice and publishes expert opinion articles reflecting intersocietal collaboration, consensus, and suggestions for further research to address these important management issues. Summary: In 2019, the intersocietal working group identified the following topics for review and interdisciplinary discussion: (i) perioperative risk stratification, (ii) the role of diagnostic radioactive iodine (RAI) imaging in initial staging, and (iii) indicators of response to RAI therapy. Conclusions: The intersocietal working group agreed that (i) initial patient management decisions should be guided by perioperative risk stratification that should include the eighth edition American Joint Committee on Cancer staging system to predict disease specific mortality, the modified 2009 ATA risk stratification system to

show abstract

Section: Introductionmentioning

confidence: 99%

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Güleç

Ahuja

Avram

et al. 2021

Thyroid

Self Cite

View full text Add to dashboard Cite

show abstract

“…The lack of uniformity in decision-making around RAI therapy results in patients receiving a wide range of RAI activities [26]. An intersocietal working group was formed in 2017 to foster collaboration in the management of patients with DTC and to progress a consensus approach [27].…”

Section: Discussionmentioning

confidence: 99%

Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience

et al. 2021

View full text Add to dashboard Cite

Objective: Our study aimed to analyse temporal trends in radioactive iodine (RAI) treatment for thyroid cancer over the past decade; to analyse key factors associated with clinical decisions in RAI dosing; and to confirm lower activities of RAI for low-risk patients were not associated with an increased risk of recurrence. Methods: Retrospective analysis of 1,323 patients who received RAI at a quaternary centre in Australia between 2008 and 2018 was performed. Prospectively collected data included age, gender, histology, and American Joint Committee on Cancer stage (7th ed). American Thyroid Association risk was calculated retrospectively. Results: The median activities of RAI administered to low-risk patients decreased from 3.85 GBq (104 mCi) in 2008–2016 to 2.0 GBq (54 mCi) in 2017–2018. The principal driver of this change was an increased use of 1 GBq (27 mCi) from 1.3% of prescriptions in 2008–2011 to 18.5% in 2017–2018. In patients assigned as low risk per ATA stratification, lower activities of 1 GBq or 2 GBq (27 mCi or 54 mCi) were not associated with an increased risk of recurrence. In patients assigned to intermediate- or high-risk categories who received RAI as adjuvant therapy, there was no difference in risk of recurrence between 4 GBq (108 mCi) and 6 GBq (162 mCi). Conclusions: Our data demonstrate an evolution of RAI activities consistent with translation of ATA guidelines into clinical practice. Use of lower RAI activities was not associated with an increase in recurrence in low-risk thyroid cancer patients. Our data also suggest lower RAI activities may be as efficacious for adjuvant therapy in intermediate- and high-risk patients.

show abstract

“…Se necesita llevar a cabo una serie de acciones para resolver los puntos de conflicto definidos en los encuentros de las sociedades científicas de 2018 y 2019, que incluye [29]:…”

Section: Futurounclassified

Actualización del tratamiento del cáncer de tiroides con radioyodo

Tamayo-Alonso

Martín-Gómez

García-Talavera

et al. 2021

ORL

View full text Add to dashboard Cite

El tratamiento del carcinoma diferenciado de tiroides (CDT) con radioyodo (RAI) se viene realizando durante más de 70 años. Sin embargo, no existe consenso en cuanto a indicaciones, dosis y otros aspectos relacionados con el cuidado de los pacientes. Es más, en los últimos años se ha cuestionado la necesidad de terapia adicional con RAI en los pacientes con carcinoma diferenciado de tiroides (CDT) tras la cirugía, como lo ha hecho la guía ATA 2015. Cuestionamiento que no ha sido suscrito por las sociedades Europea y Americana de Medicina Nuclear (EANM y SNMIM, respectivamente), lo que ha dado lugar a se produzcan encuentros (Encuentros de La Martinica) entre la EANM, la SNMIM y las Sociedades Americana (ATA) y Europea de Tiroides (ETA). Se han celebrado dos encuentros, en 2018 y 2019, en los que se establecieron unos principios (Principios de La Martinica). Estos principios y los resultados de las publicaciones más recientes, en cuanto a la potencialidad de la terapia con RAI en pacientes con CDT, van a ser objeto de desarrollo en este trabajo para llevar a cabo una actualización del tratamiento del CDT con RAI.

show abstract

Brief progress report from the intersocietal working group on differentiated thyroid cancer

Cited by 6 publications

References 1 publication

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience

Actualización del tratamiento del cáncer de tiroides con radioyodo

Contact Info

Product

Resources

About